ArticleJournal of orthopaedic case reports2025
Multisite Osteonecrosis to Long-term Corticoid Treatment: A Case Report.
Article in Journal of orthopaedic case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Osteonecrosis (ON) refers to the death of bone cells caused by a disruption in blood flow. Multiple-site osteonecrosis (MSON) is a rare condition characterized by concurrent or sequential involvement of three or more separate anatomic sites approximately 3% of ON patients. Avascular necrosis (AVN) is commonly associated with high-dose or long-term corticosteroid use, and several reports suggest that high-dose corticosteroid use is the primary risk factor for developing MSON. The ideal management of ON in a young individual remains a subject of debate. Review of literature supports Core decompression (CD) as an effective treatment option in the pre-collapse stage of ON in small to medium-sized lesions according to Ficat and Arlet Stage I and II. In the advanced stages of the disease (i.e., Stages III and IV), arthroplasty is required when joint preservation is not possible. Case Report: A 27-year-old female presented with pain in the right ankle and left shoulder. The patient was on corticosteroids. Suspected MSON by examination was later confirmed using magnetic resonance imaging. CD and bone marrow aspiration concentrate application sequentially in all affected joints in three sessions with a 2-month gap. Alendronate 70 mg once a week was advised. Tensor fascia lata muscle pedicle bone grafting was performed on both hips following two years post-primary surgery due to the continued progression of the disease. Conclusion: Therefore, young adults experiencing pain or a limited range of motion in their shoulder and ankle joints, particularly if they have a history of steroid use and no other known causes, should be checked for MSON. CD, Bone marrow aspirate concentrate application, and alendronate have decreased the rate of progression of the disease in all joints except in the hips. Tensor fascia lata muscle pedicle grafting decreased progression in the hips.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.